

General information about company			
ISCP code*		586128	
NSRF Symbol*		NS015TED	
NSRF Symbol*		NS015TED	
ISCP		09C384.0005	
Name of company		Pharm Lab Limited	
Type of company		Main Board	
Class of security		Equity	
Date of start of financial year		01-04-2024	
Date of end of financial year		31-03-2025	
Date of board meeting when results were approved		27-05-2025	
Date on which prior intimation of the meeting for considering financial results was informed to the exchange		26-05-2025	
Description of presentation currency		INR	
Level of rounding		Lakhs	
Reporting Type		Quarterly	
Reporting Quarter		Fourth quarter	
Nature of report standalone or consolidated		Standalone	
Whether results are audited or unaudited for the year to date for current period endcycle ended		Audited	
Negative Reporting		Single negative	
Description of single negative		PHARMACALITY A.L.S	
Start date and time of board meeting		27-05-2025 16:00	
End date and time of board meeting		27-05-2025 17:05	
Whether cash flow statement is applicable on company		Yes	
Type of cash flow statement		Cash flow indirect	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Whether the company has any related party?		Yes	
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?		Yes	
(i) We declare that the acceptance of listed deposits by the bank/Non-Banking Finance Company are in the terms (uniformly applicable)defined in all shareholders'aggre.		NA	
(ii) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates in savings or a term deposits of bank/Staff and Non-exclusive associations as well as in deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a dual tenure.		NA	
(iii) Whether the company is a High value debt listed entity?According to regulation 15 (1A)?		No	
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., admitting RPT disclosures in the day of results presentation?		Yes	
(b) If answer to above question is No, please explain the reason for not complying.			
Whether the company discloses its Non-Confidentiality (NFC) Policy (in compliance with Reg. 23 of SEBI (LODR) has been disclosed on the website of the Company?		Yes	
Latest date on which RPT policy is updated		15-02-2023	
Indicate Company website link for updated RPT policy of the Company		https://pharmalab.com/wp-content/uploads/2023/04/Policy-on-Related-Party-Transactions.pdf	
Whether statement in deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?		No	
No. of times funds raised during the quarter		0	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?		No	The disclosure for the Default on Loans and Debt Securities is applicable to the entity.

Financial Results -Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-01-2025	01-04-2024
Date of end of reporting period		31-03-2025	31-03-2025
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
Part I Blue color market fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months/ 6 months ended, in such case zero shall be inserted in the said column.			
1 Income			
Revenue from operations		83.7	791.9
Other income		18.53	70.95
Total income		102.63	772.85
2 Expenses			
Cost of materials consumed		0.4	109.83
Purchase of stock-in-trade		90.09	176.99
Change in inventories of finished goods, work-in-progress and stock-in-trade		-36.04	13.25
Employee benefit expense		22.39	96.2
Finance costs		0.5	2.39
Depreciation, depletion and amortisation expense		1.27	6.34
Other Expenses			
Other Expenses		34.91	180.04
Total other expenses		34.91	180.04
Total expenses		111.82	507.64
Total profit before exceptional items and tax		-9.19	165.21
Exceptional items		0	0
Total profit before tax		-9.19	165.81
Tax expense		0	0
Current tax		0	0
Deferred tax		-2.83	46.35
Total tax expenses		-2.83	46.35
Net movement in regulatory deferred account balances related to profit or loss and the related deferred tax movement		0	0
Net Profit/Loss for the period from continuing operations		8.36	139.46
Basic earnings (loss) per share from discontinued operations		0	0
Profit (loss) from discontinued operations before tax		0	0
Tax expense of discontinued operations		0	0
Net Profit (loss) from discontinued operations after tax		0	0
Share of profit (loss) of associates and joint ventures accounted for using equity method		0	0
Total profit (loss) for period		8.36	139.46
Other comprehensive income for the period		0.53	0.53
Total Comprehensive Income for the period		8.89	139.83
Total profit or loss, attributable to			
Profit or loss, attributable to owners of parent			
Total profit or loss, attributable to non-controlling interests			
Total Comprehensive Income for the period attributable to			
Complete ownership for the period attributable to owners of parent			
Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21 Details of equity share capital			
Paid-up equity share capital		1148.56	1148.56
Face value of equity share capital		10	10
Reserves excluding revaluation reserve		0	0
22 Earnings per share			
Earnings per equity share for continuing operations			
Basic earnings (loss) per share from continuing operations		-0.07	1.21
Diluted earnings (loss) per share from continuing operations		-0.07	1.21
Earnings per equity share for discontinued operations			
Basic earnings (loss) per share from discontinued operations		0	0
Diluted earnings (loss) per share from discontinued operations		0	0
Basic earnings (loss) per share from continuing and discontinued operations			
Basic earnings (loss) per share from continuing and discontinued operations		-0.07	1.21
Diluted earnings (loss) per share from continuing and discontinued operations		-0.07	1.21
Debt equity ratio		0	0
Debt service coverage ratio		0	0
Interest service coverage ratio		0	0
Disclosure of notes on financial results		Financial Information(4)	

		Whether results are audited or unaudited	Audited
		Nature of report (standalone or consolidated)	Standalone
Assets			
1 Non-current assets			
Property, plant and equipment			42.51
Capital work-in-progress			0
Investment property			0
Goodwill			0
Other intangible assets			0
Intangible assets under development			0
Biological assets other than bearer plants			0
Investments accounted for using equity method			0
Non-current financial assets			
Non-current investments			1003.08
Trade receivables, non-current			0
Loans, non-current			0
Other non-current financial assets			0.25
Total non-current financial assets			1003.33
Deferred tax assets (net)			0
Other non-current assets			0
Total non-current assets			1006.66
2 Current assets			
Investments			78.3
Current financial asset			
Current investments			0
Trade receivables, current			34.52
Cash and cash equivalents			59.34
Bank balance other than cash and cash equivalents			77.55
Loans, current			696.04
Other current financial assets			0
Total current financial assets			907.45
Current tax assets (net)			5.2
Other current assets			78.52
Total current assets			1069.47
Non-current assets classified as held for sale			596.2
Regulatory deferred account debt balances and related deferred tax Assets			0
Total assets			2471.51
Total current assets			1069.47
Non-current assets classified as held for sale			596.2
Regulatory deferred account debt balances and related deferred tax Assets			0
Total assets			2471.51
Equity and liabilities			
1 Equity			
Equity attributable to owners of parent			
Equity share capital			1148.56
Other equity			1105.71
Total equity attributable to owners of parent			2254.27
Non controlling interest			0
Total equity			2254.27
2 Liabilities			
Non-current liabilities			
Non-current financial liabilities			
Borrowings, non-current			40.60
Trade Payables, non-current			0
(A) Total outstanding dues of micro enterprises and small enterprises			0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises			0
Total Trade payable			0
Other non-current financial liabilities			0
Total non-current financial liabilities			40.60
Provisions, non-current			0
Deferred tax liabilities (net)			2.72
Deferred government assets, Non-current			0
Other non-current liabilities			0
Total non-current liabilities			43.32
Current liabilities			
Current financial liabilities			
Borrowings, current			0
Trade Payables, current			0
(A) Total outstanding dues of micro enterprises and small enterprises			21.49
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises			113.07
Total Trade payable			134.56
Other current financial liabilities			20.75
Total current financial liabilities			155.35
Other current liabilities			18.23
Provisions, current			0.28
Current tax liabilities (Net)			0
Deferred government assets, Current			0
Total current liabilities			173.86
Liabilities directly associated with assets is disposed group classified as held for sale			0
Regulatory deferred account credit balances and related deferred tax liability			0
Total liabilities			217.24
Total equity and liabilities			2471.51
Disclosure of notes on assets and liabilities			Financial Information(1)

Other Comprehensive Income			
Date of start of reporting period		01-01-2025	01-04-2024
Date of end of reporting period		31-03-2025	31-03-2025
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
Other comprehensive income / (expense) / (loss)			
1 Amount of items that will not be reclassified to profit and loss			
1 Items that will not be reclassified to Profit and Loss			
Total Amount of items that will not be reclassified to profit and loss		-0.71	-0.71
2 Items relating to items that will not be reclassified to profit or loss			
Total Amount of items that will not be reclassified to profit or loss		-0.18	-0.18
3 Amount of items that will be reclassified to profit and loss			
Total Amount of items that will be reclassified to profit and loss			
Income or expense in items that will be reclassified to profit or loss		0.00	0.00
Total Other comprehensive income		-0.53	-0.53

		Nature of report: standalone or consolidated		Standalone
Blue color market fields are non-mandatory.				
1	Statement of cash flows			
Cash flows from used in operating activities				
	Profit before tax			105.81
2	Adjustments for reconcile profit (loss)			
	Adjustments for finance costs			2.39
	Adjustments for decrease (decrease) in investments			11.23
	Adjustments for decrease (decrease) in trade receivables, current			-25.08
	Adjustments for decrease (decrease) in trade receivables, non-current			0
	Adjustments for decrease (decrease) in other current assets			-168.02
	Adjustments for decrease (decrease) in other non-current assets			0
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			0
	Adjustments for other bank balances			68.81
	Adjustments for increase (decrease) in trade payables, current			0
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			3.75
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			6.34
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			0
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			0
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses/gains			0
	Adjustments for dividend income			0
	Adjustments for interest income			50.78
	Adjustments for share-based payments			0
	Adjustments for fair value losses (gains)			0
	Adjustments for underfunded profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			0
	Other adjustments to reconcile profit (loss)			0
	Other adjustments for non-cash items			0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			-155.79
	Net cash flows from used in operating activities			38.02
3	Net cash flows from used in investing activities			
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			0
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payments for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			5.91
	Purchase of property, plant and equipment			0
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			75.86
	Cash advances and loans made to other parties			0